Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]

Background: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the per...

Full description

Bibliographic Details
Main Authors: Edwin O. Magomere, Donald D. Nyangahu, Sammy Kimoloi, Brenda A. Webala, Bartholomew N. Ondigo
Format: Article
Language:English
Published: F1000 Research Ltd 2019-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/8-1518/v1
id doaj-49b049579d9f458cb32f9ff1cedf1846
record_format Article
spelling doaj-49b049579d9f458cb32f9ff1cedf18462020-11-25T02:32:05ZengF1000 Research LtdF1000Research2046-14022019-08-01810.12688/f1000research.20083.122050Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]Edwin O. Magomere0Donald D. Nyangahu1Sammy Kimoloi2Brenda A. Webala3Bartholomew N. Ondigo4Department of Biochemistry and Molecular Biology, Egerton University, Nakuru, Nakuru, 20115, KenyaCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USADepartment of Medical Laboratory Sciences, Masinde Muliro University of Science and Technology, Kakamega, Kakamega, KenyaFaculty of Health Sciences, Egerton University, Nakuru, Nakuru, KenyaDepartment of Biochemistry and Molecular Biology, Egerton University, Nakuru, Nakuru, 20115, KenyaBackground: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the performance characteristics of a modified commercial HIVDR testing assay. Methods: A total of 26 plasma samples were used to validate and assess the accuracy, precision, reproducibility and amplification sensitivity of a modified HIVDR assay by HIV genotyping. In addition, a cost comparison between the original and the modified assay was performed using the ingredient costing approach. Results: The performance characteristics of the modified assay were in agreement with the original assay. Accuracy, precision and reproducibility showed nucleotide sequence identity of 98.5% (confidence interval (CI), 97.9–99.1%), 98.67% (CI, 98.1–99.23) and 98.7% (CI, 98.1–99.3), respectively.  There was no difference in the type of mutations detected by the two assays (χ2 = 2.36, p = 0.26). Precision and reproducibility showed significant mutation agreement between replicates (kappa = 0.79 and 0.78), respectively (p < 0.05). The amplification sensitivity of the modified assay was 100% and 62.5% for viremia ≥1000 copies/ml and <1000 copies/ml respectively. Our assay modification translates to a 39.2% reduction in the cost of reagents. Conclusions: Our findings underscore the potential of modifying commercially available HIVDR testing assays into cost-effective, yet accurate assays for use in resource-limited settings.https://f1000research.com/articles/8-1518/v1
collection DOAJ
language English
format Article
sources DOAJ
author Edwin O. Magomere
Donald D. Nyangahu
Sammy Kimoloi
Brenda A. Webala
Bartholomew N. Ondigo
spellingShingle Edwin O. Magomere
Donald D. Nyangahu
Sammy Kimoloi
Brenda A. Webala
Bartholomew N. Ondigo
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
F1000Research
author_facet Edwin O. Magomere
Donald D. Nyangahu
Sammy Kimoloi
Brenda A. Webala
Bartholomew N. Ondigo
author_sort Edwin O. Magomere
title Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
title_short Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
title_full Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
title_fullStr Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
title_full_unstemmed Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
title_sort performance characteristics of a modified hiv-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2019-08-01
description Background: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the performance characteristics of a modified commercial HIVDR testing assay. Methods: A total of 26 plasma samples were used to validate and assess the accuracy, precision, reproducibility and amplification sensitivity of a modified HIVDR assay by HIV genotyping. In addition, a cost comparison between the original and the modified assay was performed using the ingredient costing approach. Results: The performance characteristics of the modified assay were in agreement with the original assay. Accuracy, precision and reproducibility showed nucleotide sequence identity of 98.5% (confidence interval (CI), 97.9–99.1%), 98.67% (CI, 98.1–99.23) and 98.7% (CI, 98.1–99.3), respectively.  There was no difference in the type of mutations detected by the two assays (χ2 = 2.36, p = 0.26). Precision and reproducibility showed significant mutation agreement between replicates (kappa = 0.79 and 0.78), respectively (p < 0.05). The amplification sensitivity of the modified assay was 100% and 62.5% for viremia ≥1000 copies/ml and <1000 copies/ml respectively. Our assay modification translates to a 39.2% reduction in the cost of reagents. Conclusions: Our findings underscore the potential of modifying commercially available HIVDR testing assays into cost-effective, yet accurate assays for use in resource-limited settings.
url https://f1000research.com/articles/8-1518/v1
work_keys_str_mv AT edwinomagomere performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved
AT donalddnyangahu performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved
AT sammykimoloi performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved
AT brendaawebala performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved
AT bartholomewnondigo performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved
_version_ 1724821562860765184